| Literature DB >> 29997346 |
Bruno Leonardo Bozaquel-Morais1, Leonie Vogt2, Valentina D'Angelo3, Raffael Schaffrath4, Roland Klassen5, Mónica Montero-Lomelí6.
Abstract
The protein phosphatase Sit4 has been shown to be required for lipogenesis and resistance against the acetyl-CoA carboxylase inhibitor soraphen A. Since Sit4 is also required for biosynthesis of Elongator dependent tRNA modifications such as 5-methoxycarbonylmethyluridine (mcm⁵U), we investigated the relevance of tRNA modifications in lipogenesis and soraphen A response. While sit4 and Elongator (elp3) mutants copy defects in mcm⁵U formation and stress sensitivity, they do not share soraphen A sensitivity and low lipid droplet (LD) phenotypes. In contrast to sit4, we found elp3 mutants to display partial soraphen A resistance and a high LD phenotype. Screening a collection of tRNA modification mutants additionally identified the tRNA pseudo-uridine synthase gene DEG1 to be required for soraphen A sensitivity. Since deg1 and elp3 share high LD and soraphen A resistance phenotypes, these are likely caused by translational defects. In support of this notion, we observe overexpression of tRNAGlnUUG suppresses lipolysis defects of deg1 mutants. Hence, the sit4 mutation results in a composite defect including tRNA modification deficiency and loss of Snf1 kinase dephosphorylation, which induce opposite effects on LD regulation. Importantly, however, the Snf1 kinase regulatory defects of the phosphatase mutant dominate over effects on LD regulation imposed by loss of the tRNA modification alone.Entities:
Keywords: Elongator complex; Sit4; soraphen A; tRNA modification
Mesh:
Substances:
Year: 2018 PMID: 29997346 PMCID: PMC6165401 DOI: 10.3390/biom8030049
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Figure 1Phenotypes of elp3 and sit4 mutants and their responses to overexpression of tRNAGlnUUG, tRNALysUUU and tRNAGluUUC. (A) BY4741 wild type (WT), elp3 or sit4 mutants were each transformed with empty plasmid pRS425 or pQKE (over-expression of tRNAGlnUUG, tRNALysUUU and tRNAGluUUC) and subjected to drop dilution spot assays involving yeast extract peptone (YP) based media with either glucose, galactose or ethanol as the carbon source. All plates were incubated at 30 °C for 3 days. (B) The same strains as in (A) were subjected to drop dilution spot assays on yeast extract peptone dextrose (YPD) medium (carbon source glucose) cultivated at 39 °C or 40 °C or on YPD medium supplemented with a crude zymocin preparation. (C) Microtiter based measurement of growth inhibition by soraphen A. Relative growth refers to optical density (O.D 600 nm) of microcultures with indicated concentrations of soraphen A as compared to soraphen A free cultures. Measurements were carried out in triplicate and presented as mean with standard deviation.
Figure 2Soraphen A phenotype of elp3 mutants. Saccharomyces cerevisiae strains BY4741 (control) and its isogenic elp3, sit4 and snf1 mutants were grown to stationary phase and seeded at a concentration of 107, 106 or 105 cells/mL (from left to right) onto YPD medium plates containing the indicated soraphen A doses. Growth was recorded after three days. A representative result of three independent experiments is shown.
Figure 3Lipid droplet (LD) content and dynamic change in Elongator mutants as compared to the wild type (WT). Elongator mutant strains were pre-grown to stationary phase (48 h) to attain a high LD content and then seeded at low density in YPD medium at 30 °C (A) Aliquots were withdrawn at stationary phase (48 h) or (B) after 5h of growth. (C) Lipid droplet dynamics of Elongator mutants was studied during the exponential phase (lipolytic phase) of growth. Stationary cells were seeded at 0.25 O.D 600 nm in YPD. Aliquots were withdrawn at the times indicated and fixed in formaldehyde 3.7%. Afterwards the LD index was measured with the liquid fluorescent recovery (LFR) assay using Bodipy 493/503 as a probe [2] and normalized to WT. The mean ± (standard deviation) S.D. of three independent experiments is shown (* p < 0.05).
Soraphen A responses of tRNA modification and phosphatase mutants. Data were obtained from a soraphen A screening of a deletion library [33].
| Gene | Nomenclature | Description | Sensitivity Score | Response |
|---|---|---|---|---|
|
|
| depressed growth rate | +6 | RESISTANT |
|
|
| thiouridine modification | +2 | RESISTANT |
|
|
| suppressor initiation of transcription | −5 | SENSITIVE |
|
|
| Sit4 associated protein | −4 | SENSITIVE |
Figure 4Soraphen A resistance and lipolysis defect in deg1 mutants. (A) Microtiter based measurement of growth inhibition of indicated strains by soraphen A. Relative growth refers to optical density (O.D 600 nm) of microcultures with indicated concentrations of soraphen A as compared to soraphen A free cultures. Measurements were carried out in triplicate and shown as mean plus standard deviation. (B) Lipid droplet dynamics and (C) growth of BY4741 (WT) and its isogenic elp3 and deg1 mutants was determined during exponential phase of growth (6 h). The mean ± S.D. of three independent experiments is shown.
Figure 5Suppression of lipolysis defects in deg1 mutants by overexpression of tRNAGlnUUG. Wild type (WT) (A) and deg1∆ (B) cells were transformed with empty vector (h.c vector) or tRNAGlnUUG multicopy plasmid (h.c.tQ(UUG)). Strains were seeded at low density and the lipid droplet dynamics were assayed during exponential phase (6 h) in YPD medium. The mean ± S.D. of three independent experiments is shown.